公开(公告)号：WO2023009572A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/038434

申请日：2022-07-27

申请人： VERASTEM, INC. ,  FRANCIS CRICK INSTITUTE

发明人： COMA, Silvia ,  PACHTER, Jonathan A. ,  STUGLIK, Brian M. ,  DOWNWARD, Julian ,  MOLINA ARCAS, Miriam

IPC分类号： A61K31/33 ,  A61K31/18 ,  A61K31/4375 ,  A61K31/4433 ,  A61K31/00

摘要： The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).

公开(公告)号：WO2023081676A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/079109

申请日：2022-11-02

申请人： VERASTEM, INC.

发明人： STUGLIK, Brian M. ,  KOUSTENIS, Andrew ,  PACHTER, Jonathan A. ,  COMA, Silvia

IPC分类号： A61K31/506 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an effective amount of the dual RAF/MEK inhibitor, an effective amount of an antibiotic agent, and optionally an effective amount of a corticosteroid.

公开(公告)号：WO2021207230A1

公开(公告)日：2021-10-14

申请号：PCT/US2021/026000

申请日：2021-04-06

申请人： VERASTEM, INC. ,  WASHINGTON UNIVERSITY

发明人： DIPERSIO, John ,  OELSNER, Sarah ,  PACHTER, Jonathan A. ,  PATERSON, Daniel W. ,  STUGLIK, Brian M.

IPC分类号： A61K31/519 ,  A61K35/17 ,  A61P37/02

摘要： Described herein is a method of using a PI3K inhibitor in the treatment of a cytokine release syndrome, such as a cytokine release syndrome associated with a viral infection, use of a PI3K inhibitor in the treatment of an acute respiratory distress syndrome, such as an acute respiratory distress syndrome characterized by cytokine release syndrome, and kits comprising a PI3K inhibitor for said uses.

公开(公告)号：WO2021222278A1

公开(公告)日：2021-11-04

申请号：PCT/US2021/029435

申请日：2021-04-27

申请人： VERASTEM, INC.

发明人： PACHTER, Jonathan A. ,  PATERSON, Daniel ,  STUGLIK, Brian M.

IPC分类号： A61P35/00 ,  C12Q1/6886

摘要： The present invention relates to methods for treating abnormal cell growth (e.g., cancer) in a subject identified as having a KRAS mutation (e.g., KRAS G12X mutation (e.g., KRAS G12V, KRAS G12D, KRAS G12A, KRAS G12R, KRAS G12S, or KRAS G12C)) comprising administering to the subject an effective amount of a MEK inhibitor (e.g., a dual RAF/MEK inhibitor) alone or in combination with an additional agent.